Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1

Muscle and Nerve

Volumn 34, Issue 2, 2006, Pages 145-152

  Vielhaber, Stefan ^a   Jakubiczka, Sibylle ^a   Gaul, Charly ^b   Schoenfeld, Mircea Ariel ^a   Debska Vielhaber, Grazyna ^a   Zierz, Stefan ^b   Heinze, Hans Jochen ^a   Niessen, Heiko G ^a   Kaufmann, Jörn ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

1H MRS; Cerebral metabolites; Myotonic dystrophy; N acetyl aspartate; Spectroscopy

Indexed keywords

CHOLINE; CREATINE; CREATINE KINASE; DNA; MYOTONIC DYSTROPHY PROTEIN KINASE; N ACETYLASPARTIC ACID; ZINC FINGER PROTEIN; ASPARTIC ACID; DRUG DERIVATIVE; N-ACETYLASPARTATE;

ACCURACY; ADULT; ARTICLE; BRAIN ATROPHY; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DISEASE DURATION; FEMALE; GRAY MATTER; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; METABOLITE; MYOTONIC DYSTROPHY; NEUROCHEMISTRY; OCCIPITAL CORTEX; PARIETAL LOBE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOUTHERN BLOTTING; TEMPORAL LOBE; WHITE MATTER; BRAIN CORTEX; BRAIN LEVEL; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REFERENCE VALUE;

ADULT; ASPARTIC ACID; BRAIN CHEMISTRY; CEREBRAL CORTEX; CHOLINE; CREATINE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; REFERENCE VALUES;

EID: 33746662281     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20565     Document Type: Article

References (40)

1. Akiguchi I, Nakano S, Shiino A, Kimura R, Inubushi T, Handa J, et al. Brain proton magnetic resonance spectroscopy and brain atrophy in myotonic dystrophy. Arch Neurol 1999;56:325-330.
2. Antonini G, Mainero C, Romano A, Giubilei F, Ceschin V, Gragnani F, et al. Cerebral atrophy in myotonic dystrophy: a voxel based morphometric study. J Neurol Neurosurg Psychiatry 2004;75:1611-1613.
3. Bates TE, Strangward M, Keelan J, Davey GP, Munro PM, Clark JB. Inhibition of N-acetylaspartate production: implications for IH MRS studies in vivo. Neuroreport 1996;7:1397-1400.
4. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571.
5. Bungener C, Jouvent R, Delaporte C. Psychopathological and emotional deficits in myotonic dystrophy. J Neurol Neurosurg Psychiatry 1998;65:353-356.
6. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15:289-298.
7. Chang L, Ernst T, Osborn D, Seltzer W, Leonido-Yee M, Poland RE. Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats. Arch Neurol 1998;55:305-311.
8. Delaporte C. Personality patterns in patients with myotonic dystrophy. Arch Neurol 1998;55:635-640.
9. Di Costanzo A, Di Salle F, Santoro L, Bonavita V, Tedeschi G. Brain MRI features of congenital- and adult-form myotonic dystrophy type 1: case-control study. Neuromuscul Disord 2002;12:476-483.
10. Fiorelli M, Duboc D, Mazoyer BM, Blin J, Eymard B, Fardeau M, et al. Decreased cerebral glucose utilization in myotonic dystrophy. Neurology 1992;42:91-94.
11. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Harper PS. Myotonic dystrophy. London: WB Saunders; 2001.
13. Hashimoto T, Tayama M, Yoshimoto T, Miyazaki M, Harada M, Miyoshi H, et al. Proton magnetic resonance spectroscopy of brain in congenital myotonic dystrophy. Pediatr Neurol 1995;12:335-340.
14. Huber SJ, Kissel JT, Shuttleworth EC, Chakeres DW, Clapp LE, Brogan MA. Magnetic resonance imaging and clinical correlates of intellectual impairment in myotonic dystrophy. Arch Neurol 1989;46:536-540.
15. Jakubiczka S, Vielhaber S, Kress W, Kupferling P, Reuner U, Kunath B, et al. Improvement of the diagnostic procedure in proximal myotonic myopathy/myotonic dystrophy type 2. Neurogenetics 2004;5:55-59.
16. Kanowski M, Kaufmann J, Braun J, Bernarding J, Tempelmann C. Quantitation of simulated short echo time 1H human brain spectra by LCModel and AMARES. Magn Reson Med 2004;51:904-912.
17. 1H MR spectroscopy in common dementias. Neurology 2004;63:1393-1398.
18. Kassubek J, Juengling FD, Hoffmann S, Rosenbohm A, Kurt A, Jurkat-Rott K, et al. Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging study. Neurosci Lett 2003;348:73-76.
19. Kiuchi A, Otsuka N, Namba Y, Nakano I, Tomonaga M. Presenile appearance of abundant Alzheimer's neurofibrillary tangles without senile plaques in the brain in myotonic dystrophy. Acta Neuropathol 1993;82:1-5.
20. Kornblum C, Reul J, Kress W, Grothe C, Amanatidis N, Klockgether T, et al. Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2. J Neurol 2004;251:710-714.
21. Le Ber I, Martinez M, Campion D, Laquerriere A, Betard C, Bassez G, et al. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. Brain 2004;127:1979-1992.
22. Lehrl S. Mehrfachwahl-Wortschatz-Intelligenztest MWT-B. Erlangen: Straube: 1978.
23. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-867.
24. Martorell L, Monckton DG, Gamez J, Johnson KJ, Gich I, Lopez de Munain A, et al. Progression of somatic CTG repeat length heterogeneity in the blood cells of myotonic dystrophy patients. Hum Mol Genet 1998;7:307-312.
25. Meola G, Sansone V, Perani D, Colleluori A, Cappa S, Cotelli M, et al. Reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy. Neurology 1999;53:1042-1050.
26. Meola G, Sansone V, Perani D, Scarone S, Cappa S, Dragoni C, et al. Executive dysfunction and avoidant personality trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy (PROMM/DM-2). Neuromuscul Disord 2003;13:813-821.
27. Miller BL. A review of chemical issues in 1H NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991;4:47-52.
28. Mizukami K, Sasaki M, Baba A, Suzuki T, Shiraishi H. An autopsy case of myotonic dystrophy with mental disorders and various neuropathologic features. Psychiatry Clin Neurosci 1999;53:51-55.
29. Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 2004;61:1943-1947.
30. Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex 1978;14:234-244.
31. Ogata A, Terae S, Fujita M, Tashiro K. Anterior temporal white matter lesions in myotonic dystrophy with intellectual impairment: an MRI and neuropathological study. Neuroradiology 1998;40:411-415.
32. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996;2:323-325.
33. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
34. Provencher SW. Automatic quantitation of localized in vivo 1H spectra with LCModel. NMR Biomed 2001;14:260-264.
35. Schirmer T, Auer DP. On the reliability of quantitative clinical magnetic resonance spectroscopy of the human brain. NMR Biomed 2000;13:28-36.
36. Schoser BG, Kress W, Walter MC. Homozygosity for CCTG mutation in myotonic dystrophy type 2. Brain 2004;127:1868-1877.
37. Udd B, Meola G, Krahe R, Thornton C, Ranum L, Day J, et al. Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. Neuromuscul Disord 2003;13:586-589.
38. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993;13:981-989.
39. Vermersch P, Sergeant N, Ruchoux MM, Hofmann-Radvanyi H, Wattez A, Petit H, et al. Specific tau variants in the brains of patients with myotonic dystrophy. Neurology 1996;47:711-717.
40. Vielhaber S, Kaufmann J, Kanowski M, Sailer M, Feistner H, Tempelmann C, et al. Effect of creatine supplementation on metabolite levels in ALS motor cortices. Exp Neurol 2001;172:377-382.